I considered this particular statement carefully when the PR came out. The structure and word choice is purposeful.
There was some consternation on the board, at the time of release, that IPIX had wait and was only just finalizing with testing sites. By my reading I don’t believe there was need for alarm or complaint. The key phrase in the sentence is “...contracts to add additional clinical sites...”. I imagine that there were a number of testing locations willing, able and cost effective for IPIX to negotiate and execute test agreements with prior to FDA approval. I interpret the sentence to mean “additional” contracts, those waiting for FDA Approval perhaps or those that may have had IPIX-cost related to contract execution, that could now be executed.
It not possible, given public information, to know if testing has already begun. I am confident that multiple site are contracted, perhaps already testing and evaluating outcomes.
No scam stock or gravy train CEO would risk their free ride by placing their primary drug candidate in a binary PH2 event of such short duration and for an illness under such public scrutiny. Let’s face it, Brilacidin’s success or failure in this clinical test cycle will translate into the success or failure of Innovation Pharmaceuticals. IPIX decision makers are no doubt susceptible to confirmation bias but they believe in Brilacidin enough to risk the future of the company on the results of the short-duration PH2 trial. I’ll share the risk along with Leo and fellow longs.
I am long and strong in IPIX. I am an investor not a trader. I believe Brilacidin has value for IBD, antibiotics and OM among other maladies. Kevetrin waits in the wings and if even marginally potent has huge value. But if B fails now, on this stage, IPIX will have suffered a fatal blow.
